You’re using a public version of DrugPatentWatch with free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Serbia: These 22 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025

DrugPatentWatch® Estimated Loss of Exclusivity Dates in Serbia

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Serbia: These 22 Drugs Face Patent Expirations and Generic Entry From 2024 - 2025" DrugPatentWatch.com thinkBiotech, 2024 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can FORTEO (teriparatide recombinant human) generic drug versions launch?

Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Serbia Patent 58,818
Patent Title: NAPRAVA ZA IZDAVANJE LEKA SA BLOKIRAJUĆOM KARAKTERISTIKOM POGONJENOM OPRUGOM AKTIVIRANOM DAVANJEM POSLEDNJE DOZE (MEDICATION DISPENSING APPARATUS WITH SPRING-DRIVEN LOCKING FEATURE ENABLED BY ADMINISTRATION OF FINAL DOSE)

Drug Price Trends for FORTEO
FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. Additional details are available on the teriparatide recombinant human profile page.

When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Serbia Patent 51,693
Patent Title: PROCES ZA DOBIJANJE OKSIKODON HIDROHLORIDA SA MANJE OD 25 ppm 14-HIDROKSIKODEINONA (PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE)

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Serbia Patent 53,891
Patent Title: FARMACEUTSKI DOZNI OBLIK KOJI SADRŽI OKSIKODON HIDROHLORID SA MANJE OD 25 PPM 14-HIDROKSIKODEINONA (PHARMACEUTICAL DOSAGE FORM COMPRISING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE)

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Serbia Patent 54,598
Patent Title: POSTUPAK ZA DOBIJANJE KOMPOZICIJA OKSIKODON HIDROHLORIDA SA MANJE OD 25ppm 14-HIDROKSIKODEINONA (PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE COMPOSITIONS HAVING LESS THAN 25PPM 14-HYDROXYCODEINONE)

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Serbia Patent 54,941
Patent Title: PROCES ZA DOBIJANJE OKSIKODON HIDROHLORIDA SA MANJE OD 25PPM 14-HIDROKSIKODEINONA (PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25PPM 14-HYDROXYCODEINONE)

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Serbia Patent 57,000
Patent Title: PROCES ZA DOBIJANJE OKSIKODON HIDROHLORIDA SA MANJE OD 25 PPM 14-HIDROKSIKODEINONA (PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25PPM 14-HYDROXYCODEINONE)

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are two patents protecting this drug.

This drug has one hundred and fifty-one patent family members in forty-one countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can NATAZIA (dienogest; estradiol valerate) generic drug versions launch?

Generic name: dienogest; estradiol valerate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Serbia Patent 51,434
Patent Title: VIŠEFAZNI PREPARAT ZA KONTRACEPCIJU NA BAZI PRIRODNOG ESTROGENA (MULTI-PHASE CONTRACEPTIVE PREPARATION BASED ON A NATURAL ESTROGEN)

Drug Price Trends for NATAZIA
NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

When can VIZIMPRO (dacomitinib) generic drug versions launch?

Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Serbia Patent 52,119
Patent Title: 4-FENILAMINO-HINAZOLIN-6-IL-AMIDI (4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES)

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety-two patent family members in forty-eight countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

When can VITEKTA (elvitegravir) generic drug versions launch?

Generic name: elvitegravir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: Serbia Patent 52,375
Patent Title: STABILNI KRISTALI JEDINJENJA 4-OKSOHINOLINA (STABLE CRYSTAL OF 4-OXOQUINOLINE COMPUND)

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.

This drug has ninety-two patent family members in thirty-six countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

When can VITEKTA (elvitegravir) generic drug versions launch?

Generic name: elvitegravir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: Serbia Patent 64,845
Patent Title: KOMBINACIJA KOJA SE SASTOJI OD STABILNOG KRISTALA 4-OKSOHINOLINSKOG JEDINJENJA (COMBINATION COMPRISING A STABLE CRYSTAL OF A 4-OXOQUINOLINE COMPOUND)

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.

This drug has ninety-two patent family members in thirty-six countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

When can CAPRELSA (vandetanib) generic drug versions launch?

Generic name: vandetanib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Serbia Patent 51,112
Patent Title: FARMACEUTSKE KOMPOZICIJE KOJE SADRŽE ZD6474 (PHARMACEUTICAL COMPOSITIONS COMPRISING ZD6474)

CAPRELSA is a drug marketed by Genzyme Corp. There is one patent protecting this drug.

This drug has forty patent family members in thirty-three countries.

See drug price trends for CAPRELSA.

The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.

When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Serbia Patent 54,929
Patent Title: FORMULACIJA I METOD OBLOŽENE TABLETE (COATED TABLET FORMULATION AND METHOD)

Drug Price Trends for KOMBIGLYZE XR
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Serbia Patent 55,174
Patent Title: FORMULACIJA I METOD OBLOŽENE TABLETE (COATED TABLET FORMULATION AND METHOD)

Drug Price Trends for KOMBIGLYZE XR
KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?

Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Serbia Patent 54,929
Patent Title: FORMULACIJA I METOD OBLOŽENE TABLETE (COATED TABLET FORMULATION AND METHOD)

Drug Price Trends for ONGLYZA
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.

When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?

Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Serbia Patent 55,174
Patent Title: FORMULACIJA I METOD OBLOŽENE TABLETE (COATED TABLET FORMULATION AND METHOD)

Drug Price Trends for ONGLYZA
ONGLYZA is a drug marketed by Astrazeneca Ab. There is one patent protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has fifty-seven patent family members in thirty-two countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.

When can FOLOTYN (pralatrexate) generic drug versions launch?

Generic name: pralatrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 30, 2024
Generic Entry Controlled by: Serbia Patent 50,622
Patent Title: TRETMAN LIMFOMA T-ĆELIJA PRIMENOM 10-PROPARGIL-10-DIAZAAMINOPTERINA (TREATMENT OF T-CELL LYMPHOMA USING 10-PROPARGYL-10-DEAZAAMINOPTERIN)

FOLOTYN is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has thirty-one patent family members in twenty-three countries. There has been litigation on patents covering FOLOTYN

See drug price trends for FOLOTYN.

The generic ingredient in FOLOTYN is pralatrexate. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the pralatrexate profile page.

When can HALAVEN (eribulin mesylate) generic drug versions launch?

Generic name: eribulin mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 03, 2024
Generic Entry Controlled by: Serbia Patent 54,054
Patent Title: INTERMEDIJERI ZA PRIPREMU HALIHONDRINA B (INTERMEDIATES FOR THE PREPARATION OF HALICHONDRIN B)

HALAVEN is a drug marketed by Eisai Inc. There are two patents protecting this drug.

This drug has seventy-eight patent family members in twenty-six countries. There has been litigation on patents covering HALAVEN

See drug price trends for HALAVEN.

The generic ingredient in HALAVEN is eribulin mesylate. Two suppliers are listed for this generic product. Additional details are available on the eribulin mesylate profile page.

When can AEMCOLO (rifamycin) generic drug versions launch?

Generic name: rifamycin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 25, 2024
Generic Entry Controlled by: Serbia Patent 50,581
Patent Title: ORALNE ANTIMIKROBIJALNE FARMACEUTSKE KOMPOZICIJE (ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS)

AEMCOLO is a drug marketed by Redhill. There are four patents protecting this drug.

This drug has twenty-eight patent family members in twenty-one countries.

See drug price trends for AEMCOLO.

The generic ingredient in AEMCOLO is rifamycin. There are eleven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the rifamycin profile page.

When can FYCOMPA (perampanel) generic drug versions launch?

Generic name: perampanel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2024
Generic Entry Controlled by: Serbia Patent 52,752
Patent Title: KRISTAL JEDINJENJA 1,2-DIHIDROPIRIDINA I METOD ZA NJEGOVU PROIZVODNJU (CRYSTAL OF 1,2-DIHYDROPYRIDINE COMPOUND AND METHOD FOR PRODUCING SAME)

Drug Price Trends for FYCOMPA
FYCOMPA is a drug marketed by Catalyst Pharms. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has one hundred and one patent family members in thirty-three countries. There has been litigation on patents covering FYCOMPA

See drug price trends for FYCOMPA.

The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the perampanel profile page.

When can YONDELIS (trabectedin) generic drug versions launch?

Generic name: trabectedin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 29, 2024
Generic Entry Controlled by: Serbia Patent 50,510
Patent Title: FORMULACIJE KOJE SADRŽE EKTEINASCIDIN I DISAHARID

YONDELIS is a drug marketed by Janssen Prods. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in thirty-six countries. There has been litigation on patents covering YONDELIS

See drug price trends for YONDELIS.

The generic ingredient in YONDELIS is trabectedin. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the trabectedin profile page.

When can DUTREBIS (lamivudine; raltegravir potassium) generic drug versions launch?

Generic name: lamivudine; raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Serbia Patent 52,197
Patent Title: KALIJUMOVA SO INHIBITORA HIV INTEGRAZE (POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR)

DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has ninety-five patent family members in forty-three countries.

The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.

When can ISENTRESS (raltegravir potassium) generic drug versions launch?

Generic name: raltegravir potassium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2024
Generic Entry Controlled by: Serbia Patent 52,197
Patent Title: KALIJUMOVA SO INHIBITORA HIV INTEGRAZE (POTASSIUM SALT OF AN HIV INTEGRASE INHIBITOR)

Drug Price Trends for ISENTRESS
ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-five patent family members in forty-five countries.

See drug price trends for ISENTRESS.

The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.

When can BELVIQ (lorcaserin hydrochloride) generic drug versions launch?

Generic name: lorcaserin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2024
Generic Entry Controlled by: Serbia Patent 50,996
Patent Title: KRISTALNI OBLICI (R)-8-HLORO-1-METIL-2,3,4,5-TETRAHIDRO-1H-BENZAZEPIN HLORHIDRAT (CRYSTALLINE FORMS OF (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHIDRO-1H-3-BENZAZEPINE HYDROCHLORIDE)

Drug Price Trends for BELVIQ
BELVIQ is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-five patent family members in forty-five countries. There has been litigation on patents covering BELVIQ

See drug price trends for BELVIQ.

The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the lorcaserin hydrochloride profile page.

When can WAKIX (pitolisant hydrochloride) generic drug versions launch?

Generic name: pitolisant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 10, 2025
Generic Entry Controlled by: Serbia Patent 50,624
Patent Title: MONOHIDROHLORIDNA SO 1-[3-[3-(4-HLOROFENIL)PROPOKSI]PROPIL]PIPERIDINA (MONOHYDROCHLORIDE SALT OF 1- [3- [3- (4-CHLOROPHENYL) PROPOXY] PROPYL] -PIPERIDINE)

WAKIX is a drug marketed by Harmony. There are three patents protecting this drug.

This drug has sixty-one patent family members in thirty-one countries. There has been litigation on patents covering WAKIX

See drug price trends for WAKIX.

The generic ingredient in WAKIX is pitolisant hydrochloride. One supplier is listed for this generic product. Additional details are available on the pitolisant hydrochloride profile page.

When can CORLANOR (ivabradine) generic drug versions launch?

Generic name: ivabradine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Serbia Patent 50,598
Patent Title: KRISTALNI OBLIK GAMA IVABRADIN HLORHIDRATA, POSTUPAK NJEGOVE IZRADE I FARMACEUTSKE SMEŠE KOJE GA SADRŽE (CRYSTALLINE FORM GAMMA OF THE CHLORHYDRATE OF IVABRADINE, PROCESS FOR ITS PREPRATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT)

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine profile page.

When can CORLANOR (ivabradine hydrochloride) generic drug versions launch?

Generic name: ivabradine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2025
Generic Entry Controlled by: Serbia Patent 50,661
Patent Title: BETA KRISTALNI OBLIK IVABRADIN HIDROHLORIDA, POSTUPAK NJEGOVE IZRADE I FARMACEUTSKE SMEŠE KOJE GA SADRŽE (CRYSTALLINE FORM BETA OF THE CHLORHYDRATE OF IVABRADINE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT)

Drug Price Trends for CORLANOR
CORLANOR is a drug marketed by Amgen Inc. There are eight patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-seven patent family members in forty-two countries. There has been litigation on patents covering CORLANOR

See drug price trends for CORLANOR.

The generic ingredient in CORLANOR is ivabradine hydrochloride. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivabradine hydrochloride profile page.

When can XIFAXAN (rifaximin) generic drug versions launch?

Generic name: rifaximin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 03, 2025
Generic Entry Controlled by: Serbia Patent 20,070,364
Patent Title: NOVI POLIMORFNI OBLICI RIFAKSIMINA, POSTUPAK NJIHOVE PROIZVODNJE I NJIHOVA UPOTREBA U MEDICINSKIM PREPARATIMA (NEW POLYMORPHOUS FORMS OF RIFAXIMIN, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN THE MEDICINAL)

Drug Price Trends for XIFAXAN
XIFAXAN is a drug marketed by Salix Pharms. There are twenty-nine patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has two hundred and eight patent family members in forty countries. There has been litigation on patents covering XIFAXAN

See drug price trends for XIFAXAN.

The generic ingredient in XIFAXAN is rifaximin. There are fourteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rifaximin profile page.

When can XIFAXAN (rifaximin) generic drug versions launch?

Generic name: rifaximin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 03, 2025
Generic Entry Controlled by: Serbia Patent 54,570
Patent Title: NOVI POLIMORFNI OBLICI RIFAKSIMINA, POSTUPAK NJIHOVE PROIZVODNJE I NJIHOVA UPOTREBA U MEDICINSKIM PREPARATIMA (NEW POLYMORPHOUS FORMS OF RIFAXIMIN, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN THE MEDICINAL)

Drug Price Trends for XIFAXAN
XIFAXAN is a drug marketed by Salix Pharms. There are twenty-nine patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has two hundred and eight patent family members in forty countries. There has been litigation on patents covering XIFAXAN

See drug price trends for XIFAXAN.

The generic ingredient in XIFAXAN is rifaximin. There are fourteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rifaximin profile page.

When can BELEODAQ (belinostat) generic drug versions launch?

Generic name: belinostat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: Serbia Patent 52,214
Patent Title: FARMACEUTSKE FORMULACIJE HDAC INHIBITORA (PHARMACEUTICAL FORMAULATIONS OF HDAC INIBITORS)

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: Serbia Patent 52,274
Patent Title: JEDINJENJE DIARILHIDANTOINA (DIARZLHZDANTOIN COMPOUND)

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-three patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

When can XTANDI (enzalutamide) generic drug versions launch?

Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: Serbia Patent 53,967
Patent Title: DIARIL HIDANTOIN JEDINJENJA KAO ANTAGONISTI RECEPTORA ANDROGENA ZA LEČENJE RAKA (DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER)

XTANDI is a drug marketed by Astellas. There are four patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and eighty-three patent family members in thirty-four countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.